Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MARS1 | P56192 | 2/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3340425 | 0.80 | CA2 (0.46) | CA2 | |
| Hydrochloric Acid SCHEMBL3341453 | 0.78 | IDO1 (0.45) | CA2 | |
| SCHEMBL626104 | 0.77 | PNMT (0.50) | ALDH1A1HDAC1 | |
| SCHEMBL6719108 | 0.77 | ALDH1A1 (0.42) | ALDH1A1HDAC1MEN1KMT2ANPC1 | |
| SCHEMBL3225959 | 0.77 | CA2 (0.47) | CA2 | |
| SCHEMBL799654 | 0.76 | CA2 (0.64) | ALDH1A1CA2CYP2C9CYP2C19MEN1 | |
| Hydrochloric Acid SCHEMBL3818358 | 0.74 | CA2 (0.61) | ALDH1A1CA2CYP2C9CYP2C19MEN1 | |
| Hydrochloric Acid SCHEMBL8185829 | 0.74 | CA2 (0.61) | ALDH1A1CA2CYP2C9CYP2C19MEN1 | |
| SCHEMBL11290860 | 0.73 | CA2 (0.80) | ALDH1A1CA2 | |
| SCHEMBL184010 | 0.73 | OXTR (0.57) | ALDH1A1CYP2C9CYP2C19MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9192569-B2 | Formulations for infusion of type B lantibiotics | NOVACTA BIOSYSTEMS LIMITED (GB) | 2015-11-24 | — | — | US | disclosed |
| US-8729031-B2 | Compounds | NOVACTA BIOSYSTEMS LIMITED (GB) | 2014-05-20 | — | — | US | disclosed |
| EP-2603204-A2 | FORMULATIONS FOR INFUSION OF TYPE B LANTIBIOTICS | Novacta Biosystems Limited (GB) | 2013-06-19 | — | — | EP | disclosed |
| US-20130137630-A1 | FORMULATIONS FOR INFUSION OF TYPE B LANTIBIOTICS | NOVACTA BIOSYSTEMS LIMITED (GB) | 2013-05-30 | — | — | US | disclosed |
| WO-2012020219-A2 | FORMULATIONS FOR INFUSION OF TYPE B LANTIBIOTICS | NOVACTA BIOSYSTEMS LIMITED (GB) | 2012-02-16 | — | — | WO | disclosed |
| EP-2393829-A1 | ACTAGARDINE DERIVATIVES | Novacta Biosystems Limited (GB) | 2011-12-14 | — | — | EP | disclosed |
| US-20110294723-A1 | Compounds | NOVACTA BIOSYSTEMS LIMITED (GB) | 2011-12-01 | — | — | US | disclosed |
| WO-2010089544-A1 | ACTAGARDINE DERIVATIVES | NOVACTA BIOSYSTEMS LIMITED (GB) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137630-A1 | FORMULATIONS FOR INFUSION OF TYPE B LANTIBIOTICS | SLC5A2, SLC5A11, SPTSSB | ALDH1A1 4387/4885CA2 1204/4885CYP2C9 4511/4885 |
| US-20110294723-A1 | Compounds | SLC11A2, SDHA, SDHB | ALDH1A1 1147/4885CA2 3328/4885CYP2C9 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.